Calidi Biotherapeutics gets FDA go-ahead for US trial
Drug Discovery World
AUGUST 2, 2022
Biotechnology company Calidi Biotherapeutics has announced that a Phase I US clinical trial will use the company’s licensed oncolytic virotherapy platform NeuroNova to deliver an oncolytic adenovirus selectively to tumor sites in patients with recurrent high-grade glioma. . Official comments . Worldwide,?an
Let's personalize your content